BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Meiri Publishes in Nature
In this seminal study, Dr. Dedi Meiri and his team from Israel enhance our knowledge of the content, effect, and variability of cannabinoids across 36 individual cannabis cultivars.
Cannabis in palliative care: current challenges and practical recommendations
Authors: Claude Cyr, Maria Fernanda Arboleda, Sunil Kumar Aggarwal, Lynda G. Balneaves, Paul Daeninck, Andrée Néron, Erin Prosk, Antonio Vigano
Annals of Palliative Medicine, October 2018
—
Pain and symptom control challenges are common in palliative care, and the search for other therapeutic strategies is ongoing. Unfortunately, patients and their caregivers are receiving little information or support from healthcare providers regarding the increasingly popular…
Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Authors: José A. Crippa, Francisco S. Guimarães, Alline C. Campos, Antonio W. Zuardi
Frontiers in Immunology, 21 September 2018
—
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. Objectives: The aim of the present review is to describe the main advances in the development of the experimental a…
Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).
Authors: Antony J. Mersiades, Annette Tognela, Paul S. Haber, Martin Stockler, Nicholas Lintzeris, et al
BMJ open, 12 September 2018
—
INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) remains an important issue for patients receiving chemotherapy despite guideline-consistent antiemetic therapy. Trials using delta-9-tetrahydrocannabinol-rich (THC) products demonstrate limited antiemetic effect, si…
Cannabinoids and spinal cord stimulation for the treatment of failed back surgery syndrome refractory pain.
Authors: Epifanio Mondello, Domenico Quattrone, Luigi Cardia, Giuseppe Bova, et al
Journal of Pain Research, 6 September 2018
—
OBJECTIVE: This study aimed to evaluate pain and its symptoms in patients with failed back surgery syndrome (FBSS) refractory to other therapies, treated with a combination of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in association with spinal cord stimulation…
Cannabis use predicts risks of heart failure and cerebrovascular accidents: results from the National Inpatient Sample.
Authors: Aditi Kalla, Parasuram Krishnamoorthy, Akshaya Gopalakrishnan, Vincent Figueredo
Journal of Cardiovascular Medicine, September 2018
—
BACKGROUND: Cannabis for medicinal and/or recreational purposes has been decriminalized in 28 states as of the 2016 election. In the remaining states, cannabis remains the most commonly used illicit drug. Cardiovascular effects of cannabis use are not well established due to a…
Marijuana Use by Breastfeeding Mothers and Cannabinoid Concentrations in Breast Milk.
Authors: Kerri A. Bertrand, Nathan J. Hanan, Gordon Honerkamp-Smith, Brookie M. Best, Christina D. Chambers
Pediatrics, September 2018
—
BACKGROUND AND OBJECTIVE: Marijuana is the most commonly used recreational drug among breastfeeding women. With legalization of marijuana in several US states and a 1990 study in which authors documented psychomotor deficits in infants breastfed by mothers using marijuana, the…
Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα in the canine gastrointestinal tract.
Authors: Giorgia Galiazzo, Fiorella Giancola, Agnese Stanzani, Federico Fracassi, Chiara Bernardini, Monica Forni, Marco Pietra, Roberto Chiocchetti
Histochemistry and Cell Biology, August 2018
—
The endocannabinoid system (ECS) is composed of cannabinoid receptors, their endogenous ligands, and the enzymes involved in endocannabinoid turnover. Modulating the activity of the ECS may influence a variety of physiological and pathophysiological processes. A growing body o…
Cannabinoids, the Heart of the Matter.
Authors: Naghum Alfulaij, Franziska Meiners, Justin Michalek, Andrea L. Small‐Howard, et al
Journal of the American Heart Association, 13 July 2018
—
Cardiovascular disease (CVD) is a global epidemic representing the leading cause of death in some Western countries. According to the American Heart Association, a total of 92.1 million US citizens currently have ≥1 forms of CVD, with numbers expected to grow reaching up to 4…
Marijuana intoxication in a cat.
Authors: Agnieszka Janeczek, Marcin Zawadzki, Pawel Szpot, Artur Niedzwiedz
Acta Veterinaria Scandinavica, 11 July 2018
—
BACKGROUND: Cannabis from hemp (Cannabis sativa and C. indica) is one of the most common illegal drugs used by drug abusers. Indian cannabis contains around 70 alkaloids, and delta-9-tetrahydrocannabinol (delta-9-THC) is the most psychoactive substance. Animal intoxications oc…
Marijuana use and short-term outcomes in patients hospitalized for acute myocardial infarction.
Authors: Cecelia P. Johnson-Sasso, Christine Tompkins, David P. Kao, Lori A. Walker
PLoS One, 11 July 2018
—
Marijuana use is increasing worldwide, and it is ever more likely that patients presenting with acute myocardial infarctions (AMI) will be marijuana users. However, little is known about the impact of marijuana use on short-term outcomes following AMI. Accordingly, we compared…
Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence.
Authors: Emily Stockings, Dino Zagic, Gabrielle Campbell, Megan Weier, Wayne D Hall, et al
Journal of Neurology, Neurosurgery & Psychiatry, July 2018
—
Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Systematic search of Medline, Embase and PsycINFO was conducted in October 2017. Outcomes were: 50%+ seizure reduction, complete seizure freedom; improved quality of life (QoL). Tolerab…